Skip to main content
SpringerLink
Log in

Is extension of HPV vaccination to adults up to age 45 years in the US good value for money?

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kim JJ, et al. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLOS Medicine : 11 Mar 2021. Available from: URL: https://doi.org/10.1371/journal.pmed.1003534

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Is extension of HPV vaccination to adults up to age 45 years in the US good value for money?. PharmacoEcon Outcomes News 874, 20 (2021). https://doi.org/10.1007/s40274-021-7563-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7563-9

Search

Navigation